CRIS vs PRTA

For growth investors, Curis, Inc.

(CRIS) is the stronger pick with -13. 4% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Analysts rate Prothena Corporation plc (PRTA) a "Buy" — based on 28 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Prothena Corporation plc (PRTA) delivered a total return of -57.

2%, compared to -99. 7% for Curis, Inc. (CRIS). Over 10 years, the gap is even starker: PRTA returned -73. 0% versus CRIS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Prothena Corporation plc (PRTA) is the lower-risk stock at 0.

96β versus Curis, Inc. 's 1. 87β — meaning CRIS is approximately 94% more volatile than PRTA relative to the S&P 500. On balance sheet safety, Prothena Corporation plc (PRTA) carries a lower debt/equity ratio of 5% versus 30% for Curis, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Curis, Inc.

(CRIS) is pulling ahead at -13. 4% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Curis, Inc. grew EPS 91. 6% year-over-year, compared to -99. 6% for Prothena Corporation plc. Over a 3-year CAGR, CRIS leads at -2. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Curis, Inc.

(CRIS) is the more profitable company, earning -80. 3% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps -80. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRIS leads at -348. 4% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — CRIS leads at 99. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Prothena Corporation plc (PRTA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

96)). Curis, Inc. (CRIS) carries a higher beta of 1. 87 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRTA: -73. 0%, CRIS: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.